Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Edison issues update on e-Therapeutics (ETX)

5 Mar 2019 15:51

Edison Investment Research Limited Edison issues update on e-Therapeutics (ETX) 05-March-2019 / 15:51 GMT/BST


London, UK, 5 March 2019

Edison issues update on e-Therapeutics (ETX)

e-Therapeutics' (ETX) FY19 results demonstrated continued financial prudence and its focus on partnering, out-licensing and non-dilutive financing. The FY19 operating loss was £5.1m, which is the same as our estimate. The cash outflow was £3.7m, resulting in a cash balance of £5.9m at the end of FY19. Both R&D and administrative expenses had been reduced from FY18 and the recently announced Novo collaboration generated £0.04m in FY19.

We have updated our valuation to £69.4m or 26p/share, from £63.5m (24p/share), due to the impact of a stronger dollar on the dollar-based comparative transactions. All underlying assumptions remain unchanged. ETX expects more collaborations, and more visible transactions than the Novo collaboration and we would expect these to be incorporated into ETX's valuation when they occur.Click here to view the full report.

All reports published by Edison are available to download free of charge from its websitewww.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Andy Smith, +44 (0)20 3077 5700healthcare@edisongroup.comLearn more at www.edisongroup.com and connect with Edison on:LinkedIn https://www.linkedin.com/company/edison-investment-research Twitter www.twitter.com/Edison_Inv_ResYouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

784179 05-March-2019 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
31st May 20182:13 pmRNSResults of Annual General Meeting
1st May 20187:00 amRNSCollaboration with C4X Discovery Holdings PLC
4th Apr 20184:13 pmRNSNotice of AGM
27th Mar 20187:00 amRNSFull Year Results
12th Mar 20187:00 amRNSNotification of Full Year Results Date
22nd Jan 20187:00 amRNSDirector/PDMR Shareholding
15th Jan 20187:00 amRNSE-Therapeutics enters two AI collaborations
3rd Jan 20187:00 amRNSDirector/PDMR Shareholding
18th Dec 20172:31 pmRNSHolding(s) in Company
18th Dec 20178:57 amRNSDirector/PDMR Shareholding
1st Nov 20177:00 amRNSAppointment of Director
5th Oct 201711:35 amEQSEdison issues update on e-Therapeutics (ETX)
26th Sep 20177:00 amRNSInterim Results for 6 Months Ended 31 July 2017
5th Sep 20179:41 amRNSNotice of Results
22nd Aug 20172:13 pmRNSDirector/PDMR Shareholding
27th Jul 20174:46 pmRNSEdison issues update on e-Therapeutics (ETX)
27th Jul 20173:24 pmEQSEdison Investment Research Limited: Edison issues update on e-Therapeutics (ETX)
24th Jul 20177:00 amRNSOutcome of Strategic Review and Future Plans
3rd Jul 20174:50 pmRNSDirector/PDMR Shareholding
19th Jun 201710:13 amRNSTR-1: Notification of Major Interest in Shares
5th Jun 20172:21 pmRNSTR-1: Notification of Major Interest in Shares
2nd Jun 20173:19 pmRNSTR-1: Notification of Major Interest in Shares
2nd Jun 20172:50 pmRNSTR-1: Notification of Major Interest in Shares
2nd Jun 201712:02 pmRNSTR-1: Notification of Major Interest in Shares
2nd Jun 20179:00 amRNSDirector/PDMR Shareholding
31st May 20172:01 pmRNSResults of Annual General Meeting
25th May 201711:20 amRNSNotification by Director
23rd May 20174:22 pmRNSDirector/PDMR Shareholding
8th May 20173:02 pmRNSNotice of Annual General Meeting and Annual Report
3rd May 20179:00 amRNSDirector/PDMR Shareholding
19th Apr 20177:00 amRNSFinal Results
6th Apr 20177:01 amRNSNotification of Full Year Results Date
6th Apr 20177:00 amRNSNew CEO Commences at e-Therapeutics
4th Apr 20178:30 amRNSHolding(s) in Company
4th Apr 20178:30 amRNSHolding(s) in Company
16th Feb 20177:00 amRNSDirectorate Change
12th Jan 201710:38 amRNSHolding(s) in Company
9th Jan 20177:00 amRNSAppointment of CEO
4th Jan 20177:00 amRNSDirector/PDMR Shareholding
23rd Nov 20164:21 pmRNSGrant of share options and Directors' dealings
6th Oct 201610:12 amRNSDirectors' Dealings and Issue of Equity
3rd Oct 20162:03 pmRNSFurther re: Directors' Shareholdings
21st Sep 20164:06 pmRNSIssue of Equity and Directors' shareholdings
20th Sep 20167:00 amRNSHalf year results
14th Sep 201612:08 pmRNSManagement Update
9th Sep 20169:30 amRNSNotice of Half Year Results
18th Aug 20165:07 pmRNSHolding(s) in Company - Correction
18th Aug 201611:07 amRNSHolding(s) in Company
1st Aug 20164:40 pmRNSIssue of Equity
13th Jul 201610:05 amRNSBoard changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.